Following a description of the epidemiology and microbial etiology of ambulatory and hospitalized CAP, this bookprovides an in-depth review of the important new advances in therapeutics, including management of drug resistance to the three major classes of antibiotics used for treatment of CAP: β-lactams, macrolides and quinolones. All of them have advantages and disadvantages and these are put into perspective. This book highlights guideline recommendations and presents a balanced analysis to help physicians deliver the highest standard of care. In addition, the authors provide an insight into the 10% of patients who do not respond to antibiotics and could benefit from adjunctive therapies, some still under review.
This volume will be welcomed by pulmonologists and all clinicians involved in managing community-acquired pneumonia.